MIMETAS develops predictive Organ-on-a-Chip cell culture models for better, more reliable and tailored medicines. A significant gap exist between the predictive value of various in vitro and animal screening models and a patient. MIMETAS fills this gap with its OrganoPlates featuring organotypic screening models that have an improved predictability and can be screened at a high throughput.
Something looks off?